2.41Open2.46Pre Close5 Volume20 Open Interest6.00Strike Price1.21KTurnover234.94%IV9.11%PremiumDec 20, 2024Expiry Date2.05Intrinsic Value100Multiplier22DDays to Expiry0.36Extrinsic Value100Contract SizeAmericanOptions Type-0.6697Delta0.1606Gamma1.64Leverage Ratio-0.0185Theta-0.0025Rho-1.10Eff Leverage0.0035Vega
Fulcrum Therapeutics Stock Discussion
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics (NASDAQ: FULC) announced that its Phase 3 REACH trial for losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The trial showed no significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to ...
Fulcrum Therapeutics Enters Into a Collaboration and License Agreement With Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
No comment yet